The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.
about
Antituberculosis drug research: a critical overview.Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient.Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis.Efflux Activity Differentially Modulates the Levels of Isoniazid and Rifampicin Resistance among Multidrug Resistant and Monoresistant Mycobacterium tuberculosis Strains.Challenging the Drug-Likeness Dogma for New Drug Discovery in TuberculosisEfflux Pumps in Mycobacteria: Antimicrobial Resistance, Physiological Functions, and Role in Pathogenicity
P2860
The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.
@en
The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.
@nl
type
label
The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.
@en
The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.
@nl
prefLabel
The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.
@en
The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.
@nl
P2860
P50
P356
P1433
P1476
The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.
@en
P2860
P304
P356
10.2217/17460913.3.2.135
P577
2008-04-01T00:00:00Z